| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
157,280,000 |
| Market
Cap: |
13.18(B) |
| Last
Volume: |
222,409 |
Avg
Vol: |
221,797 |
| 52
Week Range: |
$52.83 - $89.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets. Co.'s Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics and cell and gene therapy. Co.'s Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
14,400 |
14,400 |
94,722 |
105,476 |
| Total Sell Value |
$1,136,004 |
$1,136,004 |
$8,231,754 |
$9,857,685 |
| Total People Sold |
2 |
2 |
3 |
4 |
| Total Sell Transactions |
2 |
2 |
4 |
8 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kummeth Charles R. |
Chief Executive Officer |
• • – |
2019-07-10 |
4 |
AS |
$212.75 |
$3,616,428 |
D/D |
(16,969) |
92,176 |
|
- |
|
| Kummeth Charles R. |
Chief Executive Officer |
• • – |
2019-07-10 |
4 |
OE |
$67.46 |
$1,144,729 |
D/D |
16,969 |
109,145 |
|
- |
|
| Kummeth Charles R. |
Chief Executive Officer |
• • – |
2019-07-09 |
4 |
AS |
$212.43 |
$3,194,340 |
D/D |
(15,037) |
92,176 |
|
- |
|
| Kummeth Charles R. |
Chief Executive Officer |
• • – |
2019-07-09 |
4 |
OE |
$67.46 |
$1,014,396 |
D/D |
15,037 |
107,213 |
|
- |
|
| Kummeth Charles R. |
Chief Executive Officer |
• • – |
2019-07-08 |
4 |
AS |
$212.75 |
$3,828,184 |
D/D |
(17,994) |
92,176 |
|
- |
|
| Kummeth Charles R. |
Chief Executive Officer |
• • – |
2019-07-08 |
4 |
OE |
$67.46 |
$1,213,875 |
D/D |
17,994 |
110,170 |
|
- |
|
| Vessey Rupert |
|
– • – |
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
147 |
147 |
|
- |
|
| Eansor N David |
SVP - Novus Biologicals |
• – – |
2019-06-12 |
4 |
AS |
$215.00 |
$670,155 |
D/D |
(3,117) |
0 |
|
- |
|
| Higgins John L |
|
– • – |
2019-06-04 |
4 |
S |
$203.67 |
$1,018,346 |
D/D |
(5,000) |
3,526 |
|
- |
|
| Higgins John L |
|
– • – |
2019-06-04 |
4 |
OE |
$63.03 |
$315,150 |
D/D |
5,000 |
8,526 |
|
- |
|
| Furlow Brenda S. |
SVP - General Counsel |
• – – |
2019-05-24 |
4 |
S |
$200.00 |
$1,080,000 |
D/D |
(5,400) |
2,189 |
|
- |
|
| Furlow Brenda S. |
SVP - General Counsel |
• – – |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,400 |
7,589 |
|
- |
|
| Hippel James |
Chief Financial Officer |
• – – |
2019-05-01 |
4 |
S |
$203.08 |
$7,107,681 |
D/D |
(35,000) |
4,382 |
|
- |
|
| Hippel James |
Chief Financial Officer |
• – – |
2019-05-01 |
4 |
OE |
$86.25 |
$3,018,750 |
D/D |
35,000 |
39,382 |
|
- |
|
| Kelderman Kim |
President, Diagnostics & Genom |
• – – |
2019-05-01 |
4 |
D |
$202.13 |
$170,598 |
D/D |
(844) |
823 |
|
- |
|
| Kelderman Kim |
President, Diagnostics & Genom |
• – – |
2019-05-01 |
4 |
OE |
$202.13 |
$336,951 |
D/D |
1,667 |
1,667 |
|
- |
|
| Steer Randolph C |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
4,226 |
|
- |
|
| Seth Alpna |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
1,253 |
|
- |
|
| Higgins John L |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
3,526 |
|
- |
|
| Baumgartner Robert V |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
8,226 |
|
- |
|
| Nusse Roeland |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
5,226 |
|
- |
|
| Keegan Joseph D |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
1,253 |
|
- |
|
| Wiens Harold J |
|
– • – |
2018-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
4,726 |
|
- |
|
| Baumgartner Robert V |
|
– • – |
2018-08-24 |
4 |
S |
$188.47 |
$942,334 |
D/D |
(5,000) |
7,712 |
|
- |
|
| Baumgartner Robert V |
|
– • – |
2018-08-24 |
4 |
OE |
$61.46 |
$307,300 |
D/D |
5,000 |
12,712 |
|
- |
|
587 Records found
|
|
Page 11 of 24 |
|
|
0.97 (1.16%) 
